BLAINJECTIONINJECTABLE
Approved
Sep 2024
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
2/8 — Basic
OTULFI (ustekinumab-aauz) by Fresenius Kabi is interleukin-12 antagonists [moa]. First approved in 2024.
Drug data last refreshed 6h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OTULFI (ustekinumab-aauz) is a monoclonal antibody that antagonizes interleukin-12, a key cytokine driver of immune-mediated inflammatory diseases. This is a biosimilar referencing the originator ustekinumab (Stelara), expanding treatment access for patients with conditions like psoriasis, psoriatic arthritis, and Crohn's disease. The IL-12 antagonism mechanism reduces pathogenic Th1 and Th17 cell differentiation.
Growth
Early-stage biosimilar in growth phase with moderate competitive pressure (30) suggests expanding commercial infrastructure and team-building opportunities for newly approved product.
Mechanism of Action
Interleukin-12 Antagonists
Pharmacologic Class:
Interleukin-12 Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
OTULFI positions professionals for career growth in biosimilar commercialization, market access, and competitive payer negotiations—critical skills in an era of biologic cost containment. Early-stage launch offers opportunity to shape market entry strategy, formulary positioning, and competitive defense against newer mechanisms.
Brand Manager
Worked on OTULFI at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.